LUNG CANCER

Results of a phase 1 study of a fourth-generation EGFR tyrosine kinase inhibitor will be presented at the International Association for the Study of Lung Cancer 2022 World Conference.

The SKYSCRAPER-01 study missed its co-primary end point of progression-free survival in patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer.

The demonstration of clinical benefit of oleclumab or monalizumab added to durvalumab vs durvalumab alone in the COAST study support further evaluation of these combinations in the larger study.

Breakthrough therapy designation has been granted to repotrectinib by the FDA for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer.

The first participants have been enrolled in the CASCADE-LUNG study, a prospective, multicenter trial.

During a live virtual event, Ravi Salgia, MD, PhD, discussed the use of immune checkpoint inhibitor monotherapy for a patient with non–small cell lung cancer with very high PD-L1 expression with participants.

As a follow-up to the success observed in the phase 2 COAST study, investigators of the phase 3 PACIFIC-9 have begun administering durvalumab in combination with monalizumab or oleclumab to patients with unresectable, stage III non–small cell lung cancer.

Nino Balanchivadze, MD, FACP, discusses the rationale for evaluating toxicity based on race in the KEYNOTE-189 study.

Treatment with avasopasem manganese reduced the incidence of radiation-induced, severe esophagitis in patients with lung cancer undergoing chemoradiotherapy, according to AESEOP trial findings.

Surface Oncology announced the initiation of new trials of the investigational agent SRF388 in patients with hepatocellular carcinoma and non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Jonathan Wesley Riess, MD, MS, discussed the case of a 72-year-old patient with non–small cell lung cancer with high PD-L1 expression.

Xiuning Le, MD, PhD, discusses counseling patients on the use of amivantamab-vmjw and mobocertinib and the sequencing of these drugs for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

During a case-based roundtable event, Estelamari Rodriguez, MD, MPH, discussed the case of a patient who had lung cancer with 3 brain metastases and a RET fusion.

Lyudmila A. Bazhenova, MD, discusses targeted therapies for patients with BRAF-mutated non–small cell lung cancer.

Fast track designation has been granted by the FDA to ONC-392, an anti-CTLA-4 monoclonal antibody used for the investigational treatment of patients with metastatic non–small cell lung cancer.

Before closing out her discussion on novel therapy for EGFR exon 20–positive NSCLC, Zofia Piotrowska, MD, shares her hopes for future developments in care.

Practical advice regarding the selection and management of amivantamab or mobocertinib in patients diagnosed with EGFR exon 20–positive NSCLC.

Comprehensive insight on the two novel, targeted agents approved for the management of EGFR exon 20–positive NSCLC following frontline therapy.

Expert oncologist Zofia Piotrowska, MD, reviews the case of a patient managed with frontline chemotherapy after receiving a diagnosis of stage 4 NSCLC.

Before closing out his discussion on novel therapy in EGFR exon 20 insertion–positive NSCLC, expert Joel Neal, MD, PhD, highlights ongoing clinical trials and the importance of testing.

Expert Joel Neal, MD, PhD, shares personal experience and highlights adverse event management strategies with amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC.

The trial results of CHRYSALIS and EXCLAIM, which investigated amivantamab and mobocertinib, respectively, as second-line therapy for EGFR exon 20 insertion–positive NSCLC.

A comprehensive discussion on novel second-line agents amivantamab and mobocertinib, approved for EGFR exon 20 insertion–positive non–small cell lung cancer.

Expert perspective on the treatment armamentarium for EGFR exon 20 in non–small cell lung cancer.

Expert Joel Neal, MD, PhD, shares his perspectives on the frontline management of NSCLC and optimal strategies for molecular profiling in this setting.